India has overtaken the US on clinical trials but struggles with regulation

Key Points

• India overtook the US in clinical trials due to its large patient population and infrastructure advancements.
• Concerns arise over unethical practices in the expanding clinical trial sector, affecting credibility and safety.
• A growing healthcare infrastructure plays a crucial role in attracting global clinical trials despite regulatory issues.
• Regulatory frameworks may need enhancement to ensure ethical standards in India's clinical trial landscape.

Abstract